Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119169) titled 'A single-arm, open clinical trial of Sindilizumab combined with preoperative chemotherapy for conversion treatment of unresectable esophageal squamous cell carcinoma' on Feb. 24.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Zhengzhou University
Condition:
Esophageal carcinoma
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2025-08-29
Target Sample Size: Cohort A: Unresectable Esophageal Squamous Cell Carcinoma:48;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=281006
...